Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Recbio Technology CoFRA:G93 24 Receivables Turnover is 2.74 as of Dec. 2025. GuruFocus rates FRA:G93 with a GF Score™ of 24/100. The stock has 6 warning signs investors should review. Among 847 Biotechnology companies, Jiangsu Recbio Technology Co ranks worse than 78.75% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Jiangsu Recbio Technology Co's Revenue for the
six
months ended in Dec. 2025 was €0.22 Mil. Jiangsu Recbio Technology Co's average Accounts Receivable for the
six
months ended in Dec. 2025 was €0.08 Mil.
Hence, Jiangsu Recbio Technology Co's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.74.
Jiangsu Recbio Technology Co (FRA:G93) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Jiangsu Recbio Technology Co Receivables Turnover Related Terms
Jiangsu Recbio Technology Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Recbio Technology Co Receivables Turnover Chart
FRA:G93 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Jiangsu Recbio Technology Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Recbio Technology Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Recbio Technology Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Jiangsu Recbio Technology Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Recbio Technology Co (FRA:G93) has a Receivables Turnover of 2.74 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Jiangsu Recbio Technology Co and its competitors. According to the industry distribution chart, Jiangsu Recbio Technology Co ranks #667 out of 847 companies in the Biotechnology industry, placing it in the top 78.7%.
Is Jiangsu Recbio Technology Co's Receivables Turnover too high?
Jiangsu Recbio Technology Co's current Receivables Turnover is 2.74. The Biotechnology industry median Receivables Turnover is 5.28. Jiangsu Recbio Technology Co's value of 2.74 is 48.1% below this industry median. Based on the distribution chart, Jiangsu Recbio Technology Co ranks #667 out of 847 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Recbio Technology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Recbio Technology Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Recbio Technology Co ranks #667 out of 847 companies for Receivables Turnover. This places Jiangsu Recbio Technology Co in the lower half of its industry. The industry median Receivables Turnover is 5.28. Jiangsu Recbio Technology Co's value of 2.74 is 48.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Recbio Technology Co's current Receivables Turnover of 2.74 is 48.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Jiangsu Recbio Technology Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Recbio Technology Co's current Receivables Turnover is 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Recbio Technology Co stock overvalued right now?
Jiangsu Recbio Technology Co (FRA:G93) has a current Receivables Turnover of 2.74. The current Receivables Turnover is 2.74 and 48.1% below the Biotechnology industry median of 5.28. Jiangsu Recbio Technology Co's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Jiangsu Recbio Technology Co (FRA:G93), the current Receivables Turnover is 2.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangsu Recbio Technology Co Ltd is a vaccine company focused on the research, development, and commercialization of vaccines, with a high-value vaccine portfolio driven by in-house technologies. It has built three vaccine technology platforms: novel adjuvants, protein engineering, and immune evaluation. The company's portfolio currently consists of various vaccines, covering diseases such as cervical cancer, herpes zoster, and respiratory syncytial virus. It has two core strategic products, namely REC610, a novel adjuvanted recombinant shingles vaccine, which is currently in the stage of marketing application in China, and REC603, a recombinant HPV 9-valent vaccine under phase three clinical trial.
24GF Score
Get the complete analysis for FRA:G93
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:G93 has been successfully added to your 
